Subscribe free

Intestine and Lower Gastrointestinal Tract ·

Pouch Rediversion: Salvage Strategy for Failing Ileoanal Pouches

Rediversion with an ileostomy was a safe, important first step in pouch salvage, with subsequent surgery for noninflammatory indications showing significantly higher pouch salvage rates than for inflammatory complications. Overall, 52% of patients underwent successful pouch salvage after rediversion, with a 5-year pouch survival rate of 94.5% for noninflammatory indications. Rediversion can be a helpful strategy in managing failing ileoanal pouches, providing valuable insights into post-salvage outcomes.

Journal Article by Uchino T, Lincango EP (…) Holubar SD et 11 al. in Inflamm Bowel Dis

© The Author(s) 2024. Published by Oxford University Press on behalf of Crohn’s & Colitis Foundation. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
© The Author(s) 2024. Published by Oxford University Press on behalf of Crohn’s & Colitis Foundation. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

read the whole article in Inflamm Bowel Dis

open it in PubMed

Summaries are written to help you decide what to read. They do not replace the full paper.

Free · 5 minutes a day

Get every new paper in Intestine and Lower Gastrointestinal Tract.

Plus the Daily Selection: the five most relevant papers of the day, each cut to its key points.

Specialty newsletters: every new paper in your field, as a list of titles linked to the source. Daily Selection: the five that matter, cut to their key points.

FreeNo spamOne-click unsubscribe

More in Intestine and Lower Gastrointestinal Tract

The latest stitches

Br J Surg5 Nov 2026

Rectal cancer and liver spread: similar outcomes

Removing the rectal tumor and liver spread in one operation did not clearly raise complications or hurt survival compared with two separate operations, a French national study found.

Lancet4 Nov 2026

Colorectal cancer: shorter chemo, fewer side effects

A Japanese randomized trial found that a 14-day schedule of trifluridine-tipiracil plus bevacizumab keeps patients with metastatic colorectal cancer alive as long as the standard 28-day schedule, with far less toxicity.

All papers in Intestine and Lower Gastrointestinal Tract →